1207989-32-9 Usage
Uses
Used in Pharmaceutical Industry:
Linezolid is used as an antibiotic for treating infections caused by Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Its effectiveness against these resistant strains makes it a valuable addition to the arsenal of antibiotics available for healthcare professionals.
However, it is important to note that linezolid can have adverse effects, including nausea, diarrhea, and headaches. Therefore, its use should always be under the supervision of a healthcare professional to ensure patient safety and optimal treatment outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 1207989-32-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,0,7,9,8 and 9 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1207989-32:
(9*1)+(8*2)+(7*0)+(6*7)+(5*9)+(4*8)+(3*9)+(2*3)+(1*2)=179
179 % 10 = 9
So 1207989-32-9 is a valid CAS Registry Number.
1207989-32-9Relevant academic research and scientific papers
Discovery of the first potent and selective αvβ5 integrin inhibitor based on an amide-containing core
Lippa, Rhys A.,Barrett, John,Pal, Sandeep,Rowedder, James E.,Murphy, John A.,Barrett, Tim N.
supporting information, (2020/09/02)
Integrins αvβ5 and αvβ3 are closely related, proangiogenic members of the wider RGD-binding integrin family. Due to their high sequence homology, the development of αvβ5-selective compounds
GLUCAGON ANTAGONISTS
-
Page/Page column 91-92, (2016/01/01)
Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharm
GLUCAGON ANTAGONISTS
-
Page/Page column 49, (2010/04/03)
Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharm
